Amaral T et al. Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001). ASCO 2024;Abstract 9572.
Amaria RN et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. ASCO 2024;Abstract 9515.
Ascierto PA et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. ASCO 2024;Abstract 9504.
Baramidze et al. A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. ASCO 2023;Abstract TPS9602.
Blank CU et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. ASCO 2024;Abstract LBA2.
Couselo E et al. Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study. ASCO 2024;Abstract 9554.
Daver D et al. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). ASCO 2023;Abstract TPS9594.
Gross ND et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol 2023;24(11):1196-205. Abstract
Hamid O et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. ASCO 2023;Abstract 9501.
Hassel JC et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med 2023;389(24):2256-66. Abstract
Hauschild AH et al. Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. ASCO 2024;Abstract 9500.
Khushalani et al. A phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma. ASCO 2024;Abstract TPS9611.
Ladwa R et al. A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. ASCO 2024;Abstract 9514.
Luke JJ et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol 2024;42(14):1619-24. Abstract
Maubec E et al. Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (cSCCs). ESMO 2023;Abstract 1139P.
Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388(9):813-23. Abstract
Rapisuwon S et al. Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309). ASCO 2024;Abstract 9509.
Robert C et al. Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 2023;41(24):3998-4003. Abstract
Tawbi HA et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. ASCO 2024;Abstract 9524.
Thomas S et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. ASCO 2024;Abstract 9505.
Weber JS et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. ASCO 2024;Abstract LBA9512.
Weber JS et al. Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma. ASCO 2024;Abstract 9538.
Wermke M et al. Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. ESMO Immuno-Oncology Congress 2023;Abstract 1190.
Wong MK et al. Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial. ASCO 2024;Abstract 9517.